


**MINUTES OF REDRESSAL COMMITTEE MEETING FOR REDRESSAL OF GRIEVANCES OF DIFFERENT FIRMS AGAINST
TENDER OF MEDICINE ITEMS (GROUP-01) FOR THE FINANCIAL YEAR 2025-26 HELD ON 22-07-2025 AT 09:30 AM IN THE
MEETING ROOM PURCHASE CELL QUAID-E-AZAM MEDICAL COLLEGE B.V.HOSPITAL, BAHAWALPUR.**

Presentations of the different firms were discussed as per agenda & decisions were made accordingly.

Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
01	M/S Stallion Pharmaceutical, Lahore	Lot No. 30 Syp. Amoxycillin (as Sodium) + Clavulanic Acid (as Potassium) 312.5mg/5ml, 60ml / 90ml	Non responsive due to less than 65% Marks in Marking Criteria = 5+10+0+0+12+5+2+ 2+0+0+5 (41/80).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The committee reviewed the documents of firm and raised marks of experience of product in private sector from 0 to 03, & Experience of product in public sector from 0 to 10 (5+10+3+10+12+5+2+2+0+0+5) = 54/80. Hence the committee declared the firm responsive for Lot No.30.
02	M/S Atco Laboratories Limited, Karachi	Lot No. 49 Tab . Aspirin 75mg Enteric Coated Blister Pack		The firm submitted grievance that quoted item was uploaded against lot No. 01 instead of Lot No. 49. The firm requested to kindly consider the Lot 01 against lot No. 49.	The Committee scrutinized the record and discussed the matter in details. The committee rejected the firm presentation as uploading of technical bid in wrong Lot No. could not be considered by procuring agency.
03	M/S SEARLE Pharmaceuticals,	Lot No. 46 Inj. Moxifloxacin 400mg/250ml e Hanger	Non responsive due to less than 65% Marks in Marking Criteria = 0+10+0+3+9+5+6+0 +2+5+5+ (45/80).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The firm provided the Drug Registration , but the firm failed to provide complete import documents of API source. Hence committee rejected the firm presentation & upheld the decision of technical advisory committee for Lot No. 46.




Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
04	M/S Hiranis Pharmaceutical, Karachi	Lot No. 183 Tab. Rosuvastatin 10mg Blister Pack	Non responsive due to less than 65% Marks in Marking Criteria = 05+10+10+0+6+5+6 +2+0+4+1 (49/80).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The committee reviewed the documents of firm provided with grievance presentation and raised marks of V Treatment Plant from 0 to 03, & available at pharmacies from 1 to 04 (5+10+10+0+09+5+6+2+0+4+4) = 55/80. Hence the committee declared the firm responsive for Lot No. 183.
04	M/S Hiranis Pharmaceutical, Karachi			The firm submitted grievance & requested for consider remaining lots not upload the E-PAD website.	The Committee scrutinized the record and discussed the matter in details. The committee rejected the firm presentation as uploading of technical bid in wrong Lot No. could not be considered by procuring agency.
05	M/S Bosch Pharmaceutical, Karachi	Lot No. 29 Inj. Amoxycillin (as Sodium) 1g + Clavulanic Acid (as Potassium) 200mg e WFI		The firm submitted grievance pleaded against M/S Stallion Pharma that, i. Recently published evaluation report by Director General Health service Punjab described detailed physical inspection of pharmaceutical, manufacturing unit. i. One of batches of Inj. Amoxycillin (as Sodium) 1g + Clavulanic Acid supplied by M/S Stallion Pharma during previous year were declared substandard by DTL of Punjab.	The Committee scrutinized the record and discussed the matter in details. The committee observed that:- i. DGHS evaluation report has no effect on our technical evaluation. ii. M/S Stallion Pharma submitted affidavit with false claim that none of the supplied batches of Inj. Amoxycillin (as Sodium) was declared substandard by any DTL. As one of batches of Amoxycillin (as Sodium) 1g + Clavulanic Acid (as Potassium) 200mg e WFI supplied by stallion Pharma was declared substandard by DTL. Hence vide TRA No. 01-10097009967. In the light of above observation the committee accepted the Plea of M/S Bosch Pharma & declared the M/S Stallion Pharma non-responsive against Lot No. 29.

Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
06	M/S Hoechst Pakistan Limited, Karachi	Lot No. 198 Inj. Low Molecular Weight Heparin (Enoxaprin 40mg) Lot No. 199 Inj. Low Molecular Weight Heparin (Enoxaprin 60mg) Lot No. 200 Inj. Low Molecular Weight Heparin (Enoxaprin 80mg)		<p>The firm submitted grievance pleaded against all other companies under Rule 67 (2)</p> <p>M/S BF Biosciences Limited, Rwp,</p> <p>M/S Himmel Pharmaceuticals Pvt Ltd, Karachi</p> <p>M/S Scilife Pharma Pvt Ltd, Karachi</p> <p>The firm requested to accept their life saving original and globally accepted brand Clexane.</p>	<p>The Committee scrutinized the record and discussed the matter in details. The committee rechecked the documents. The committee rejected the firm presentation pleaded against M/S BF Biosciences Limited, Rwp. M/S Himmel Pharmaceuticals Pvt Ltd, Karachi and M/S Scilife Pharma Pvt Ltd, Karachi.</p>


Handwritten signatures and initials in blue and green ink at the bottom of the page.



Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
07	M/S BF Biosciences Limited, Rwp,	Lot No. 198 Inj. Low Molecular Weight Heparin (Enoxaprin 40mg) Lot No. 199 Inj. Low Molecular Weight Heparin (Enoxaprin 60mg)	Non responsive due to due to non availability of Biosimilar studies	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The firm submitted bioequivalence studies of Enoxaprin. The committee observed that DRAP has issued registration of product on the basis of these bioequivalence studies. Hence the committee decided to accept the firm grievance on the DRAP registration. Furthermore the firm provided documents which were reviewed & accepted by committee & marks increased in marking criteria for Lot 198, 199 (5+10+10+10+12+5+6+0+2+4+3) = 67/80. And Lot No. 200 (5+10+3+0+12+5+6++2+2+4+5) = 54/80. Hence the committee declared the firm responsive.
		Lot No. 200 Inj. Low Molecular Weight Heparin (Enoxaprin 80mg)	Non responsive due to due to non availability of Biosimilar studies & less than 65% Marks in Marking Criteria = 5+10+3+0+12+0+6++2+2+4+3 (47/80).	The firm submitted grievance & requested for re-consideration.	



Handwritten signatures and initials in blue and green ink are present below the table. There are three distinct blue signatures/initials and one green signature on the right side.



Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
08	M/S Himmel Pharmaceuticals Pvt Ltd, Karachi	Lot No. 198 Inj. Low Molecular Weight Heparin (Enoxaprin 40mg) Lot No. 199 Inj. Low Molecular Weight Heparin (Enoxaprin 60mg)	Non responsive due to due to non availability of Biosimilar studies & less than 65% Marks in Marking Criteria = 3+10+3+7+5+5+5+5 = (43/75).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The firm submitted bioequivalence studies of Enoxaprin. The committee observed that DRAP has issued registration of product on the basis of these bioequivalence studies. Hence the committee decided to accept the firm grievance on the basis of DRAP registration. Furthermore the committee rechecked the documents. After rechecking, the marks remained same. The firm declared non responsive for Lot No 198, 199 due to less than 65% Marks in Marking Criteria.
		Lot No. 200 Inj. Low Molecular Weight Heparin (Enoxaprin 80mg)	Non responsive due to due to non availability of Biosimilar studies	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The firm submitted bioequivalence studies of Enoxaprin. The committee observed that DRAP has issued registration of product on the basis of these bioequivalence studies. Hence the committee decided to accept the firm grievance on the basis of DRAP registration. The committee declared the firm responsive for Lot No. 200.



Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
09	M/S Inventor Pharma Pvt Ltd, Karachi	Lot No. 13 Inj. Cefoperazone 1g + Sulbactam 1g e WFI	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+0+0+12+5+6+1+2+5+0 (43/80).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The committee reviewed the documents of firm and raised marks of API source from 5 to 10, experience of product in Private sector from 0 to 10 (10+7+0+10+12+5+6+1+2+5+0) = 58/80. Hence the committee declared the firm responsive for Lot No.13.
		Lot No. 14 Inj. Cefotaxime 1g e WFI	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+0+0+12+5+6+2+2+5+0 (44/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of API source from 5 to 10, & Experience of product Private sector from 0 to 07 (10+7+07+0+12+5+6+2+2+5+0) = 56/80. Hence the committee declared the firm responsive for Lot No.14.
		Lot No. 16 Inj. Ceftriaxone 1g e WFI	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+0+3+12+5+6+0+0+5+0 (43/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of API source from 5 to 10, raised marks Reference Standard from 0 to 02 & raised marks Stability Study from 0 to 02 (10+7+0+3+12+5+6+2+2+5+0) = 52/80. Hence the committee declared the firm responsive for Lot No.16.
		Lot No. 202 Inj. Tranexamic Acid 500mg	Non responsive due to less than 65% Marks in Marking Criteria = 10+7+0+0+12+5+6+1+2+5+0 (48/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of Experience of product supply in Private sector from 5 to 07, raised marks Stability Study from 0 to 02 & raised marks Reference Standard from 0 to 02 (10+7+7+0+12+5+6+2+2+5+0) = 56/80. Hence the committee declared the firm responsive for Lot No.202.
		Lot No. 203. Cap. Tranexamic Acid 500mg Blister Pack	Non responsive due to less than 65% Marks in Marking Criteria = 10+7+0+0+12+5+6+1+2+5+0 (48/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of Experience of product supply in Private sector from 5 to 07, raised marks Stability Study from 0 to 02 & raised marks Reference Standard from 01 to 02 (10+7+7+0+12+5+6+2+2+5+0) = 56/80. Hence the committee declared the firm responsive for Lot No.203.

Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
10	M/S Mega Pharmaceutical, Lahore	Lot No. 69 Tab/Cap Piroxicam 20mg Blister Pack	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+3+0+3+5+6+0+0+4+5 (38/80).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The committee reviewed the documents of firm and raised marks of Water Treatment Plant from 0 to 03, (5+7+3+0+6+5+6+0+0+4+5) = 41/80. Hence the committee declared the firm Non responsive & upheld the decision of technical advisory committee for Lot No 69.
		Lot No. 70 Cap/Tab. Tizanidine 4mg Blister Pack	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+7+0+3+5+6+2+0+4+5 (44/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of Water Treatment Plant from 0 to 03, (5+7+7+0+6+5+6+2+0+4+5) = 47/80. Hence the committee declared the firm Non responsive & upheld the decision of technical advisory committee for Lot No 70.
		Lot No. 137 Tab. Amlodipine 5mg + Valsartan 80mg	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+7+0+3+5+6+2+1+4+5 (45/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of Water Treatment Plant from 0 to 03, (5+7+7+0+6+5+6+2+1+4+5) = 48/80. Hence the committee declared the firm Non responsive & upheld the decision of technical advisory committee for Lot No 137.
		Lot No. 169 Tab. Losartan Potassium 50mg	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+7+5+3+5+6+2+0+4+5 (49/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of Water Treatment Plant from 0 to 03, (5+7+7+5+6+5+6+2+0+4+5) = 52/80. Hence the committee declared the firm responsive for Lot No. 169
		Lot No. 207 Cap/Tab. Esomeprazole 40mg	Non responsive due to less than 65% Marks in Marking Criteria = 5+7+10+0+3+5+6+2+0+4+5 (47/80).	The firm submitted grievance & requested for re-consideration.	The committee reviewed the documents of firm and raised marks of Water Treatment Plant from 0 to 03, (5+7+10+0+6+5+6+2+0+4+5) = 50/80. Hence the committee declared the firm Non responsive & upheld the decision of technical advisory committee for Lot No 207.




Sr No.	Name of Firm	Lot Nos.	Decision of TAC	Grievances	Decision
11	M/S Scilife	Lot No. 199 Inj. Low Molecular Weight Heparin (Enoxaprin 60mg)	Non responsive due to due to non availability of Biosimilar studies & less than 65% Marks in Marking Criteria = 07+10+3+10+5+5+5 +0= (45/75).	The firm submitted grievance & requested for re-consideration.	The Committee scrutinized the record and discussed the matter in details. The firm sub bioequivalence studies of Enoxaprin. The committee observed that DRAP had issued registration of product on the basis of these bioequivalence studies. Hence the committee decided to accept the firm grievance on the l DRAP registration. Furthermore the firm provided documents w were reviewed & accepted & hence marks increased in marking criteria the complianc quality standard product marks raised from availability of quoted product marks raised 0 to 10 (07+10+3+10+5+5+5+10) = 55/75. Hence the committee declared the firm respo for Lot No. 199.

A.M.S Admin
SAH Bahawalpur
(Member)

A.M.S Admin
PIC Bahawalpur
(Member)

A.M.S Admin
B.V. Hospital Bahawalpur
(Member)

Prof. Dr. Sh. Attique-ur-Rehman,
Professor of Surgery Department
(Member)

Prof. Dr. Mumtaz Rasool
Head of Urology Department
(Member)

Prof. Dr. Shahadat Hussain
Head of Cardiology, BVH
(Member)

Prof. Dr. Mughees Ameen
Head of Plastic Surgery Department,
QAMC, BVH Bahawalpur
(Chairman of the Committee)